Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, shared an article by Alicia F. C. Okines on X:
“Out in Nature Medicine – the combo of tucatinib/trastuzumab +/- fulvestrant yields relevant activity (ORR 42%, PFS 9.5 mo) in pts with HER2 mutant MBC (mostly HR+, half lobular).
Well tolerated combo, to be considered in these pts before moving to chemo.”
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.
Authors: Alicia F. C. Okines, et al.
Paolo Tarantino, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School. He completed a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023